The Company is engaged in the research, development and commercialization of novel drugs for the treatment of central nervous system disorders.


Updates from The Motley Fool

Latest updates on Amarin from Fool.com.  The Fool has written over 300 articles on Amarin.
3 Growth Stocks to Own in 2018

If you're looking for outstanding growth vehicles to own next year, these three biotech stocks ar...



Stock Performance

View Interactive AMRN Charts
Sponsored by

Key Data Points

Primary metrics and data points about Amarin.
Current Price: $2.94
Prev Close: $2.99
Open: $3.00
Bid: $2.90
Ask: $3.49
Day's Range: $2.93 - $3.05
52wk Range: $2.82 - $4.60
Volume: 3,679,278
Avg Vol 2,008,261
Market Cap: $796M
P/E (ttm): -11.96
EPS (ttm): ($0.25)
Div & Yield: $0.00 (0.0%)

Company Rating

What our community thinks about Amarin.
CAPS Rating 4 out of 5
 
306 Outperform
26 Underperform
CAPS All Stars
 
30 Outperform
6 Underperform

How do you think Amarin will perform against the market?



You pick for Amarin is winning

Score: +97.74
Call: Outperform
Time Frame: Five Plus Years
Start Price: $18.24
Start Date: 3/29/2007
Gain/Loss: +$152.4%
S&P Gain/Loss: +$54.7%

Powered by Motley Fool CAPS


CEO Rating

The single most important factor in a company's success is the team that's leading the company.

Joseph S. (Joe) Zakrzewski, CEO

16% Approve

Based on 5 Ratings

Powered by Glassdoor

Business Summary

Industry, sector and description for Amarin.

The Company is engaged in the research, development and commercialization of novel drugs for the treatment of central nervous system disorders.

  • Exchange: NASDAQ
  • Sector: Healthcare
  • Industry: Drug Makers